Get the Stockscreener App
1.27
12.39%
0.14
Pre-market:
1.22
-0.05
-3.94%
Pacific Biosciences Of California Inc stock is traded at $1.27, with a volume of 10.16M.
It is up +12.39% in the last 24 hours and down -12.41% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.13
Open:
$1.12
24h Volume:
10.16M
Relative Volume:
0.95
Market Cap:
$347.81M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-0.8467
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
+0.00%
1M Performance:
-12.41%
6M Performance:
-22.56%
1Y Performance:
-62.76%
1-Day Range:
$1.12
$1.28
1-Week Range:
$1.08
$1.36
52-Week Range:
$1.08
$3.70
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.27 | 347.81M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
131.93 | 228.81B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.05 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
377.46 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.86 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.05 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Pacific Biosciences of California appoints CFO - MSN
PacBio names Jim Gibson as new CFO By Investing.com - Investing.com South Africa
Pacific Biosciences of California Names Jim Gibson CFO - Marketscreener.com
PacBio names Jim Gibson as new CFO - Investing.com India
Jim Gibson To Join PacBio As Chief Financial Officer - MarketScreener
Tech Giant CFO Who Raised $1B+ Joins PacBio: Ex-Tesla, Apple Executive to Drive Growth - Stock Titan
Publications March 2025 - Pacific Biosciences
Assessing Pacific Biosciences: Insights From 6 Financial Analysts - Benzinga
ATTENTION PACB SHAREHOLDERS: Investors Who Lost Money on Pacific Biosciences of California, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation - ACCESS Newswire
Here's Why You Should Retain PacBio Stock in Your Portfolio Now - MSN
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors - MSN
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - MSN
PacBio, Take2 Resolve DNA Sequencing Patent Infringement Dispute - Bloomberg Law
Is Pacific Biosciences of California, Inc. (PACB) the Most Volatile Stock Under $3 For Day Trading? - Insider Monkey
10 Most Volatile Stocks Under $3 For Day Trading - Insider Monkey
Inspiring the next generation of scientists: How multidisciplinary science powers PacBio technology - Pacific Biosciences
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks - The Globe and Mail
Pacific Biosciences of California (PACB) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
ATTENTION PACB SHAREHOLDERS: Investors who lost money on Pacific Biosciences of California, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
Pacific Biosciences secures extended lease with rent abatement By Investing.com - Investing.com Australia
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) - MSN
Pacific Biosciences secures extended lease with rent abatement - Investing.com
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Re - GuruFocus
2024 SMRT Conserve grant winners - Pacific Biosciences
1 Healthcare Stock to Target This Week and 2 to Turn Down - The Globe and Mail
Pacific Biosciences of California, Inc. to Host Earnings Call - ACCESS Newswire
Selected publications from February 2025 - Pacific Biosciences
Pacific Biosciences COO Mark Van Oene sells $9,125 in company stock - Investing.com Australia
Pacific Biosciences CEO sells $17,583 in stock By Investing.com - Investing.com South Africa
Pacific Biosciences CEO sells $17,583 in stock - Investing.com
ARK Investment Management LLC Buys 2,637,961 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) - MarketBeat
Rare Disease Month: Putting People First - Pacific Biosciences
Pacific Biosciences of California (PACB) Stock Moves -1.18%: What You Should Know - MSN
Investor Network: Pacific Biosciences of California, Inc. to Host Earnings Call - ACCESS Newswire
Chromosome-level genome assembly and improved annotation of onion genome ( Allium cepa L.) - Nature.com
Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock - Seeking Alpha
Pacific Biosciences of California's (PACB) "Neutral" Rating Reaffirmed at Piper Sandler - MarketBeat
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Sells $45,776.12 in Stock - MarketBeat
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):